Age and weight did not show a clinically significant impact on 177Lu-DOTATATE exposure or kidney and bone marrow dosimetry values, confirming that flat dosing at adult dosage is appropriate for adolescents. 177Lu-DOTATATE with 7.4 GBq of activity, administered over 4 cycles 8 wk apart, is a well-tolerated therapeutic dosing regimen for adolescent patients with gastroenteropancreatic neuroendocrine tumors or pheochromocytomas and paragangliomas.

3 days ago

PK/PD data • Journal

SSTR (Somatostatin Receptor)

SSTR positive

Lutathera (lutetium Lu 177 dotatate)

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)

P1, N=30, Recruiting, University of California, San Francisco | Not yet recruiting --> Recruiting

6 days ago

Enrollment open

Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan (clinicaltrials.gov)

P=N/A, N=753, Not yet recruiting, Novartis Pharmaceuticals

9 days ago

New trial

FOLH1 positive

Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors (clinicaltrials.gov)

P1, N=10, Recruiting, University of Wisconsin, Madison | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026

9 days ago

Trial completion date • Trial primary completion date

SSTR (Somatostatin Receptor)

SSTR positive

Lutathera (lutetium Lu 177 dotatate)

11d

CLOVER-WaM: Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom (clinicaltrials.gov)

P2, N=120, Active, not recruiting, Cellectar Biosciences, Inc. | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Jun 2026

11 days ago

Trial completion date • Trial primary completion date

iopofosine I-131 (CLR 131)

11d

KKS-312: Adjuvant radioligand therapy in neuroendocrine tumors (2024-518236-36-00)

P2/3, N=160, Recruiting, Philipps-Universitaet Marburg | Not yet recruiting --> Recruiting

11 days ago

Enrollment open

SSTR (Somatostatin Receptor)

Lutathera (lutetium Lu 177 dotatate)

11d

Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas (clinicaltrials.gov)

P1, N=30, Active, not recruiting, Cellectar Biosciences, Inc. | Trial primary completion date: Dec 2025 --> Aug 2026

11 days ago

Trial primary completion date

CD34 (CD34 molecule)

iopofosine I-131 (CLR 131)

12d

CGCJ904A12101: A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors (2025-521702-18-00)

P1, N=62, Not yet recruiting, Novartis Pharma AG | N=27 --> 62

12 days ago

Enrollment change

12d

A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients (clinicaltrials.gov)

P=N/A, N=1247, Completed, Novartis Pharmaceuticals

12 days ago

New trial • Real-world evidence

carboplatin • docetaxel • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Provenge (sipuleucel-T)

13d

SWOG S0016: S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma (clinicaltrials.gov)

P3, N=571, Completed, SWOG Cancer Research Network | Active, not recruiting --> Completed

13 days ago

Trial completion

CD20 positive

Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Bexxar (iodine I 131 tositumomab)

13d

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan (clinicaltrials.gov)

P2, N=87, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting

13 days ago

Enrollment closed

Pluvicto (lutetium Lu 177 vipivotide tetraxetan)